For a small and undisclosed upfront fee it is licensing the rights to 60 new chemical entities based on the core structure of sulforaphane, the active ingredient in the company's lead product SFX-01 for breast cancer.
Evgen said it will use its Sulforadex platform to synthesise and stabilise the newly acquired compounds.
As well as the upfront payment, the firm’s new partners will receive cash as the drug or drugs hit certain milestones. They will also receive a royalty on any sales that won’t exceed 1%.
Chief executive Stephen Franklin said: “We are delighted to acquire the exclusive worldwide licensing rights to these novel compounds.
“The University of Seville has conducted an innovative medicinal chemistry programme based on sulforaphane and, like sulforaphane, these novel compounds have a requirement for our patented stabilisation technology.
“These new compounds give us the opportunity to lead the intellectual property space around sulforaphane and to build a drug development pipeline targeting several therapeutic markets within neurology and oncology."